Marshall Wace’s Moderna MRNA Stock Holding History

Marshall Wace’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$406K	Sell	5,800 -38,800	-87%	-$2.01M	﹤0.01%	2601
2026 Q1	$2.27M	Buy	44,600 +43,400	+3,617%	+$2.02M	﹤0.01%	1715
2025 Q4	$35.4K	Sell	1,200 -358,400	-100%	-$9.74M	﹤0.01%	2799
2025 Q3	$9.29M	Buy	+359,600	New	+$10M	0.01%	938
2023 Q2	–	Sell	-40,600	Closed	-$6.24M	–	2787
2023 Q1	$6.24M	Sell	40,600 -99,100	-71%	-$16.3M	0.01%	890
2022 Q4	$25.1M	Buy	139,700 +18,600	+15%	+$3.04M	0.06%	383
2022 Q3	$14.3M	Buy	121,100 +11,700	+11%	+$1.78M	0.03%	629
2022 Q2	$15.6M	Buy	109,400 +72,900	+200%	+$10.4M	0.03%	594
2022 Q1	$6.29M	Buy	36,500 +34,000	+1,360%	+$5.72M	0.01%	1203
2021 Q4	$634K	Buy	+2,500	New	+$731K	﹤0.01%	2682

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Marshall Wace's MRNA Position: Q2 2026 in Review

Marshall Wace reduced its Moderna (MRNA) stake by 100% in Q2 2026, selling an estimated $6.91M and leaving 163 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

Marshall Wace first reported a position in MRNA in Q2 2019 and has held it in 21 quarters since. The position peaked at $139M in Q1 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Marshall Wace held 163 shares of Moderna worth $11.7K as of Q2 2026.
Marshall Wace sold 133,652 Moderna shares in Q2 2026, an estimated $6.91M.
Moderna made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #3071 holding.
Marshall Wace first reported a position in Moderna in Q2 2019 and has held it in 21 quarters since.
Marshall Wace's Moderna position peaked at $139M in Q1 2022.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.